280 related articles for article (PubMed ID: 32869649)
21. Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
Nakagawa K; Matsumura K; Scory T; Farris MS; Larkin-Kaiser KA; Kikkawa H; Ivanova JI; Wilner KD
Future Oncol; 2021 Jan; 17(1):103-115. PubMed ID: 32959703
[No Abstract] [Full Text] [Related]
22. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
[TBL] [Abstract][Full Text] [Related]
23. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
[TBL] [Abstract][Full Text] [Related]
24. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
[TBL] [Abstract][Full Text] [Related]
25. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
26. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
[TBL] [Abstract][Full Text] [Related]
27. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
[TBL] [Abstract][Full Text] [Related]
28. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
29. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
[TBL] [Abstract][Full Text] [Related]
30. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
Remon J; Steuer CE; Ramalingam SS; Felip E
Ann Oncol; 2018 Jan; 29(suppl_1):i20-i27. PubMed ID: 29462255
[TBL] [Abstract][Full Text] [Related]
32. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
[TBL] [Abstract][Full Text] [Related]
33. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
Remon J; Planchard D
Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
[TBL] [Abstract][Full Text] [Related]
34. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
[TBL] [Abstract][Full Text] [Related]
35. REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
Hou B; Lu X; Gao DC; Liu QX; Zhou D; Zheng H; Dai JG
Pak J Pharm Sci; 2021 Jul; 34(4):1459-1468. PubMed ID: 34799322
[TBL] [Abstract][Full Text] [Related]
36. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
[TBL] [Abstract][Full Text] [Related]
37. The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
Li D; Li M; Li H; Shi P; Chen M; Yang T
Dis Markers; 2023; 2023():5272125. PubMed ID: 37077340
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Ariyasu R; Yanagitani N; Tadokoro K; Yamaguchi T; Uchibori K; Kitazono S; Fujita N; Katayama R; Nishio M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):517-525. PubMed ID: 32948919
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and network meta-analysis of first-line therapy for advanced
Franek J; Cappelleri JC; Larkin-Kaiser KA; Wilner KD; Sandin R
Future Oncol; 2019 Aug; 15(24):2857-2871. PubMed ID: 31298572
[TBL] [Abstract][Full Text] [Related]
40. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
